Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-08-01
2006-08-01
Parkin, J. S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
07083795
ABSTRACT:
An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using β-propiolactone, a non-ionic detergent, particularly n-octyl-α-D-glucopyranoside and n-octyl-β-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.
REFERENCES:
patent: 4591505 (1986-05-01), Prince
patent: 4664912 (1987-05-01), Wiktor et al.
patent: 4732683 (1988-03-01), Georgiades et al.
patent: 5071758 (1991-12-01), Stott et al.
patent: 5200179 (1993-04-01), Bordt et al.
patent: 5223254 (1993-06-01), Paradiso et al.
patent: 222415 (1986-11-01), None
patent: 310317 (1988-09-01), None
patent: 91 00104 (1991-01-01), None
patent: 91/00104 (1991-01-01), None
patent: 93 21310 (1993-10-01), None
Kuchler, R.J.: Virus growth and purification: Biochem. Meth. in Cell Culture and Vir. : pp. 168-205, 1977.
Mbiguino, et al.: Purification of human respiratory syncytial virus . . . : J. of Vir. Meth.: 31: pp. 161-170, 1991.
Preston, et al.: Infectious respiratory syncytial virus (RSV) effectively . . . : JID: 165: pp. 819-825,1992.
White, et al.: In vitro effect of ascorbic acid on infectivity . . . : J. of Clin. Micorbio.: pp. 527-531, 1986.
McIntosh, et al.: Respiratory Syncytial Virus: Field's Virology: 2nd Ed.:pp. 1045-1072, 1990.
Mbiguino, et al.: Purification of human respiratory syncytial virus. . . : J. of Vir. Meth. :31: pp. 161-170, 1991.
White, et al: In vitro effect ascorbic acid on infectivity. . . : J. of Clin. Microbio.: pp. 527-531, 1986.
McIntosh, et al.: Respiratory Syncytial Virus: Fields's Virology: 2nd Ed.: pp. 1045-1072, 1990.
Downing, et al. : Active respiratory syncytial virus. . . : J. Vir. Meth.: 38: pp. 215-228, 1992.
Hall, C.B., 1994, “Prospects for a respiratory syncytial virus vaccine”, Science 265:1391-1394.
Tristram, D.A., et al., 1993, “Respiratory syncytial virus vaccines: can we improve on nature?”, Ped. Ann. 22:715-718.
Toms, G.L., 1995, “Respiratory syncytial virus—how soon will we have a vaccine?”, Archiv. Dis. Child. 72:1-3.
Murphy, B.R., et al., 1994, “An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV) vaccines”, Vir. Res. 32:13-36.
Salkine, A.R. and N.J. Roberts, Jr., 1992, “Recent observations regarding the pathogenesis of recurrent respiratory syncytial virus infections: implications for vaccine development”, Vaccine 10(8):519-523.
Glezen, W.P., Paredes, A. Allison, J.E., Taber, L.H. and Frank, A.L. (1981). J. Pediatr. 98, 708-715.
Chanock, R.M., Parrot, R.H., Connors, M., Collins, P.L. and Murphy, B.R. (1992) Pediatrics 90, 137-142.
Martin, A. J., Gardiner, P.S. and McQuillin, J. (1978). Lancet ii, 1035-1038.
Robbins, A., and Freeman, P. (1988) Sci. Am. 259, 126-133.
Glezen, W.P., Taber, L.H., Frank, A.L. and Kasel, J.A. (1986) Am. J. Dis. Child. 140, 543-546.
Katz, S.L. New vaccine development establishing priorities. vol. 1. Washington: National Academic Press. (1985) pp. 397-409.
Wertz, G.W., Sullender, W.M. (1992) Biotech. 20, 151-176.
McIntosh, K. and Chanock, R.M. (1990) in Fields Virology (Fields, B.M., and Knipe, D.M. eds.) pp. 1045-1075, Raven Press, Ltd., New York.
Walsh, E.E., Hall, C.B., Briselli, M., Brandiss, M.W. and Schlesinger, J.J. (1987) J. Infect. Dis. 155, 1198-1204.
Walsh, E.E., Hruska, J. (1983) J. Virol. 47, 171-177.
Levine, S., Kleiber-France, R., and Paradiso, P.R. (1987) J. Gen. Virol. 69, 2521-2524.
Anderson, L.J., Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernie, B.F., Stone, Y. and McIntosh, K. (1985),J. Infect. Dis. 151, 626-633.
Johnson, P.R., Olmsted, R.A., Prince, G.A., Murphy, B.R., Alling, D.W., Walsh, E.E. and Collins, P.L. (1987) J. Virol. 61 (10), 3163-3166.
Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, I.W., Minamitani, M. and Meiklejohn, G. (1969) Am. J. Epidemiol. 89 (4), 435-448.
Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) Am. J. Epidemiol. 89 (4), 449-463.
Kapikian, A.Z., Mitchell, R.H., Chanock, R.M., Shvedoff, R.A. and Stewart, C.E. (1969) Am. J. Epidemiol. 89 (4), 405-421.
Kim, H.W., Arrobio, J.O., Pyles, G., Brandt, C.D Camargo, E., Chanock, R.M. and Parrott, R.H. (1971 Pediatrics 48, 745-755.
Wright, P.F., Belshe, R.B., Kim, H.W., Van Voris, L.P. and Chanock, R.M. (1982) Infect. Immun. 37 (1), 397-400.
Wright, P.F., Chinozaki, T. and Fleet, W. (1976) J. Pediatr. 88, 931-936.
Belshe, R.B., Van Voris, L.P. and Mufson, M.A. (1982) J. Infect. Dis. 145, 311-319.
Murphy, BR., Prince, G.A., Walsh, E.E, Kim H.W., Parrott, R.H., Hemming V.G., Rodriguez, W.J., and Chanock. J. Clin. Microbiol. (1986), 24 (2), 197-202.
Connors, M., Collins, P.L., Firestone, C-Y., Sotnikov, A.V., Waitze, A., Davis, A.R., Hung, P.P., Chanock R.M., Murphy, B. (1992) Vaccine, 10, 475-484.
Prince, G.A., Jenson, A.B., Hemming, V.G., Murphy, E.R., Walsh, E.E., Horswood, R.L and Chanock, R.L. (1986 b) J. Virol. 57 (3), 721-728.
Piedra, P.A., Camussi, F. and Ogra, P.L. (1989) J. Gen. Virol. 70, 325-333.
Prince et al, J. Virol 61,6 1851-1854, Jun. 1987.
Hemming V.G. et al, J. Infect. Dis., 152:1083-1087 (1985).
Budowsky, E.I. and Zheleznova, N.V. (1991) Vaccine 9 (6), 319-325.
Budowsky, E.I., Friedman, E.A., Zheleznova, N.V. and Noskov, F.S. (1991) Vaccine 9 (6), 398-402.
Stephan, W., Dichtelmuller, H., Prince, A.M., Brotman, B. and Huima, T. J. Med. Virol. (1988), 26 (3), 227-232.
Barth, R., Gruschkau, H., Bijok, U., Hilfenhaus, J., Hinz, J. and Milcke, L. J. Biol. Stand. (1994) , 12 (1), 29-46.
Salkind, A.R. and Roberts N.J. (1992) Vaccine. 10, 519-523.
Murphy, B.R., Prince, G.A., Collins, P.L. Coelingh, K.V.W., Olmsted R.A., Spriggs, M.K., Parrott, R.H., Kim, H-W., Brandt, C.D. and Chanock, R.M. (1988) Virus Research 11, 1-15.
Kimman, T.G. and Westenbrink, F. (1990) Archives of Virology 112, 1-25.
Wertz, G.W. and Sullender, W.M. (1992) Biotechnology 20: 151-176.
La Via, W.V., Marks, M.I., Stutman H.R. (1992) J. Pediatrics 121, 503-510.
Collins et al, Vaccine 8 (2) : 164-168, 1990.
Preston et al, Journal of Infectious Disease 165 (5) 819-825, 1992.
Mbiguino et al, Journal of Virological Methods 31:161-170, 1991.
Downing et al, Journal of Virological Methods 32:215-228, 1992.
Hall C.B., Science 265:1393-1394, 1994.
White et al, Journal of Clinical Microbiology, vol. 24, No. 4:527-531 1986.
Murphey-Corb et al., Vaccines 90: Mod. Approaches New Vaccines Incl. Prev. AIDS, [Conf.], 7th(1990), Meeting Date 1989, 393-9. Editor(s): Brown, Fred. Publisher: Cold Spring Harbor Lab., Cold Spring Harbor, NY.
Kuchler R.J., Biochemical Methods in Cell Culture & Virology, Dowden, Hutchingon & Ross, Inc. Stroudsburg, PA 168-205, 1977.
Groothuis et al (N. Engl. J. Med. 329:1524-1530).
Bissell et al, 1980, PNAS USA, 77:2711-2715.
Solo et al, 1978, App. Env. Microbiol 36:68-75.
Coe, J.E. and Prince, G.A.—Immunology 1996, 88, pp. 323-330.
Ewasyshyn Mary E.
Klein Michel H.
Sanhueza Sonia E.
Parkin J. S.
Sanofi Pasteur Limited
Sim & McBurney
LandOfFree
Inactivated respiratory syncytial viral vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inactivated respiratory syncytial viral vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inactivated respiratory syncytial viral vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677408